A clinical research on the multi-omics analysis in the clinical feature, therapeutic effect and prognosis in chronic airway diseases

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035380

Enrollment

Unknown

Registered

2020-08-09

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic airway disease

Interventions

Asthma group:None

COPD group:None

Control group:none

Eligibility

Sex/Gender

All

Age

14 Years to 65 Years

Inclusion criteria

Inclusion criteria: Asthma group: 1. Patients were eligible with aged 14 to 65 years, conforming to diagnostic criteria of GINA 2020; 2. Regular treatment with inhaled corticosteroids and long-acting beta-agonists for at least 6 months; 3. At least one asthma attack within the past one year, or the ACT score under 20 after regular treatment with inhaled corticosteroids and long-acting beta-agonists. COPD group: 1. Patients were eligible with aged 14 to 65 years, conforming to diagnostic criteria of GOLD 2020; 2. Regular treatment with inhaled corticosteroids and long-acting beta-agonists, or long-acting muscarinic cholinergic antagonist for at least 6 months; 3. In stage 3 of COPD according to GOLD criteria, or the mMRC questionnaire above grade 2 and CAT score above 10. Control group: 1. Aged 14 to 65 years old; 2. No history of chronic airway diseases, such as bronchial asthma, chronic obstructive pulmonary disease, bronchiectasis; 3. Lung function test without obstructive ventilation dysfunction.

Exclusion criteria

Exclusion criteria: 1. History of intravenous glucocorticoid or other immunosuppressive agents use within one month; 2. Acute infection, history of antibiotic use within one month; 3. Acute cerebral infarction, acute myocardial infarction, acute pulmonary embolism within three month.

Design outcomes

Primary

Measure	Time frame
Microbial species by 16S/ITS;mass spectrometric detection;whole transcriptome resequencing;lung function;chest CT scan;bronchoalveolar lavage fluid;bronchial epithelium biopsy;serum IgE;serum eosinophils count;COPD mMRC questionnaire;COPD CAT score;asthma ACT score;	—

Secondary

Measure	Time frame
blood RT;CRP;	—

Countries

China

Contacts

Public ContactGu Wen

Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University

guwen@xinhuamed.com.cn+86 13621892405

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026